"Myrbetriq® (Mirabegron) Improved BPH Urinary Symptoms in Men Already on Tamsulosin (Flomax)"
Steven Kaplan, MD, professor of urology at the Icahn School of Medicine at Mount Sinai discusses his new study. “We explored whether mirabegron (Myrbetriq), an agent approved for the treatment of overactive bladder (OAB), improved patient outcomes when added to tamsulosin. This was a randomized, double-blind, placebo-controlled, multi-center study enrolling 715 male patients 40 years of age and older.” He added, “Overall, the results demonstrated the addition of mirabegron to tamsulosin significantly improved symptoms of urinary urgency and frequency.”
— Steven A. Kaplan, MD, Professor, Urology, Icahn School of Medicine at Mount Sinai, Director, Men’s Wellness Program, Mount Sinai Health System
Early Clinical Trial Tests Immune-Boosting Therapy Before Prostate Cancer Surgery
Oct 30, 2025 View All Press Releases
New AI Tool by Mount Sinai Researchers Could Reshape Prostate Cancer Care
Sep 23, 2024 View All Press Releases
Immunotherapy After Bladder Cancer Surgery Shows Excellent Cancer-free Survival Rates
May 14, 2022 View All Press ReleasesMount Sinai Receives $1 Million Grant for Prostate Cancer Research
Dec 05, 2019 View All Press Releases